Abstract
Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly in western countries, but the prevalence is apparently different between races and countries. Until now, an epidemiologic study of PMR is limited in Korea. We retrospectively evaluated the clinical data of 78 patients with PMR who were treated in 5 tertiary hospitals, and analyzed initial laboratory data, symptoms, therapeutic responses, and prognostic factors for relapse 1 year after treatments. Sixty percent of patients had pain in both shoulder and hip girdles with 10.6 weeks of duration, 75.9 ± 32.7 mm/h of erythrocyte sedimentation rate (ESR), and 6.2 ± 6.4 mg/dl of C-reactive protein. The rate of relapse and remission at 1 year was 38.4 and 2.5 %, respectively. The rate of overall relapse was 46.1 %, and the relapse occurred mostly in a year, especially between 6 and 12 months after diagnosis. There were more female in relapse group (88.9 %, p = 0.037), and cumulative steroid dose of 1 year was significantly higher in relapse group (5.5 ± 2.7 vs. 4.4 ± 2.5 g, p = 0.018). Independent risk factors for relapse were initial CRP ≥ 2.5 mg/dl (OR 6.296, p = 0.047) and the use of hydroxychloroquine (OR 6.798, p = 0.035). Initial dosage or tapering speed of steroid did not influence on prognosis. In Korean patients with PMR, baseline clinical characteristics and relapse rate were similar to previous studies, but our patients accompanied no giant cell arteritis and showed lower remission rate as well as delayed therapeutic response and later occurrence of relapse. More aggressive management would be needed according to the clinical status of patients.
Similar content being viewed by others
References
Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261–271
Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, Pompei O, Blanco R (2010) Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 11:1077–1087
Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279–1283
Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26–35
Dasgupta B, Salvarani C, Schirmer M et al (2008) Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 35:270–277
Bird HA, Leeb BF, Montecucco CM et al (2005) A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 64:626–629
Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25:130–136
Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190
Salvarani C, Cantini F, Macchioni P et al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 41:1221–1226
Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179–2184
Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65–73
Smith CA, Fidler WJ, Pinals RS (1983) The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County Tennessee. Arthritis Rheum 26:1214–1219
Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439
Wilke WS, Wysenbeek AJ, Krall PL, Segal AM (1985) Masked presentation of giant-cell arteritis. Cleve Clin Q 52:155–159
Myklebust G, Gran JT (1996) A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 35:1161–1168
Salvarani C, Cantini F, Niccoli L et al (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53:33–38
Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847–850
Hutchings A, Hollywood J, Lamping DL et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57:803–809
Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716–722
Ornetti P, Guillibert-Karras C, Garrot JF et al (2011) Study of professional practices among rheumatologists in Burgundy: initial corticotherapy in polymyalgia rheumatica. Clin Rheumatol 30:51–56
Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, Espigol-Frigole G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169:1839–1850
Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315–321
Cantini F, Salvarani C, Olivieri I et al (2000) Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30:17–24
Caporali R, Cimmino MA, Ferraccioli G et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493–500
Acknowledgments
This work was supported by Konkuk University in 2012.
Conflict of interest
The authors have no conflicts of interest of any kind to declare in the materials or services referred to in this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J.H., Choi, S.T., Kim, J.S. et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33, 1475–1480 (2013). https://doi.org/10.1007/s00296-012-2580-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2580-4